Endometrial liquid based cytology (LBC) is useful for the diagnosis of undifferentiated uterine sarcoma (UUS)

2017 ◽  
Vol 56 (1) ◽  
pp. 33-38
Author(s):  
Kazumi IWASAKI ◽  
Tetsuji KUROKAWA ◽  
Akiko SHINAGAWA ◽  
Masaki MORI ◽  
Yasuhiro SAKAI ◽  
...  
Keyword(s):  
Uterine Sarcoma ◽  
Liquid Based Cytology ◽  
Undifferentiated Uterine Sarcoma

scholarly journals Undifferentiated Uterine Sarcoma Presenting as a Pathologic Humerus Fracture

2010 ◽  
Vol 175 (9) ◽  
pp. 691-692 ◽  
Author(s):  
Michelle N. Gonzalez ◽  
Megan J. DiFurio ◽  
Michael J. Sundborg ◽  
Charles A. Leath
Keyword(s):  
Uterine Sarcoma ◽  
Humerus Fracture ◽  
Undifferentiated Uterine Sarcoma

Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature

2009 ◽  
Vol 19 (2) ◽  
pp. 245-248 ◽  
Author(s):  
Frédéric Amant ◽  
An Coosemans ◽  
Vincent Renard ◽  
Els Everaert ◽  
Ignace Vergote
Keyword(s):  
Clinical Benefit ◽  
Response Rate ◽  
Uterine Sarcoma ◽  
Current Data ◽  
Clinical Impact ◽  
High Grade ◽  
Review Of The Literature ◽  
Uterine Sarcomas ◽  
Previously Treated ◽  
Undifferentiated Uterine Sarcoma

AbstractThe clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.

Pulmonary Metastasis of Undifferentiated Uterine Sarcoma Forming Fluid-Containing Cyst

2017 ◽  
Vol 26 (2) ◽  
pp. 180-184 ◽  
Author(s):  
Genki Usui ◽  
Hirotsugu Hashimoto ◽  
Jun Matsumoto ◽  
Masaaki Akahane ◽  
Hajime Tsunoda ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Uterine Sarcoma ◽  
Low Grade ◽  
Serous Fluid ◽  
Secondary Degeneration ◽  
Endometrial Stroma ◽  
Stromal Sarcoma ◽  
Cystic Changes ◽  
High Grade Sarcoma ◽  
Undifferentiated Uterine Sarcoma

Undifferentiated uterine sarcoma (UUS) is a high-grade sarcoma with no specific differentiation; however, it exhibits variable positivity for CD10 as an immunohistochemical marker of endometrial stroma, suggesting immunohistochemical differentiation into endometrial stroma. It has been reported that some low-grade endometrial stromal sarcoma pulmonary metastatic foci show cystic changes; however, whether pulmonary metastatic UUS foci are solid or cystic remains undescribed. A 63-year-old woman underwent a hysterectomy. The subsequent pathologic diagnosis was UUS. After the operation, she was treated with chemotherapy; however, pulmonary solitary shadow was radiologically detected. Eight months after the gynecologic operation, her pulmonary lesion was surgically resected. Pathologically, the lesion consisted of a cyst containing serous fluid with thick whitish wall composed of tumor cells, which led to the diagnosis of metastatsis of UUS. The cyst seemed to be formed via secondary degeneration. She remains healthy without recurrence 28 months after her first visit to our hospital.

scholarly journals Notable response of SMARCA4-deficient undifferentiated uterine sarcoma to palliative radiotherapy

2021 ◽  
pp. 100728
Author(s):  
Mariko Kurokawa ◽  
Takuya Shimizuguchi ◽  
Kei Ito ◽  
Maki Takao ◽  
Toru MotoiMD ◽  
...  
Keyword(s):  
Palliative Radiotherapy ◽  
Uterine Sarcoma ◽  
Undifferentiated Uterine Sarcoma
Sign in / Sign up

Export Citation Format

Share Document